Skip to content

Author

Isabel Barragán

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Germline HLA and KIR Variation and Disease Control After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: Exposure Definition Shapes the Signal

Immune checkpoint inhibitors (ICIs) benefit only a minority of patients with advanced non-small cell lung cancer (NSCLC). Whether germline human leukocyte antigen (HLA) or killer cell immunoglobulin-like receptor (KIR) variation identifies them is unclear, partly because studies define HLA exposures differently. We ask...

Andrea González-Hernández, Alberto Ríos, J. L. Onieva et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.